Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : BLUE    crawled date : 2021 - 03 - 29    save search
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma
Published: 2021-03-27 (Crawled : 10:41) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
BLUE | $1.02 7.03% 6.11% 8.2M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
food therapy drug t-cell car-t
Gainers vs Losers
67% 33%

Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.